SCHEMBL7528977

SCHEMBL7528977

COC(=O)c1ccc(N(C(C)=O)c2ccc(C(=O)Nc3ccc(/C=C/c4ccc(S(=O)(=O)O)cc4)cc3C(=O)OC)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.41
PTGS2 P35354 1/20 0.40
KDM4E B2RXH2 6/20 0.39
ALDH1A1 P00352 5/20 0.39
HSD17B10 Q99714 3/20 0.39
TSHR P16473 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 2/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 4/20 0.38
MAPK10 P53779 1/20 0.38
POLB P06746 2/20 0.38
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7528984 1.00 PTPN1 (0.41) PTPN1PTGS2KDM4EALDH1A1HSD17B10
SCHEMBL7645682 0.88 ALDH1A1 (0.43) PTPN1PTGS2KDM4EALDH1A1HSD17B10
SCHEMBL7534111 0.82 MAPT (0.55) KDM4EALDH1A1KMT2AMEN1LMNA
SCHEMBL7534117 0.82 MAPT (0.55) KDM4EALDH1A1KMT2AMEN1LMNA
SCHEMBL7650295 0.81 MEN1 (0.47) PTPN1ALDH1A1KMT2AMEN1LMNA
SCHEMBL7529853 0.76 APP (0.47) PTPN1KDM4EALDH1A1HSD17B10TSHR
SCHEMBL7529846 0.76 APP (0.47) PTPN1KDM4EALDH1A1HSD17B10TSHR
SCHEMBL7527352 0.76 MAPT (0.57) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL7527364 0.76 MAPT (0.57) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL7527005 0.75 KDM4E (0.51) KDM4EALDH1A1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US claimed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US disclosed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers SLC2A1, SLC2A8, SLC2A2 PTPN1 1380/4885PTGS2 2143/4885KDM4E 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.